Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration [Published by Global Data]

Price for Single User $ 5946 USD :: Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell RegenerationSummaryType 1 diabetes (T1D) is a chronic condition that occurs as a

Read the full article here

Related Articles